Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo
30 mg of CVL-231 once-daily improved PANSS total score at 6 weeks by 12.7 points compared with placebo (p=0.023)
20 mg of CVL-231 twice-daily improved PANSS total score at 6 weeks by 11.1 points compared with placebo (p=0.047)
No meaningful differences in gastrointestinal side effects, extrapyramidal symptoms or weight gain compared with placebo
Cerevel plans to advance CVL-231 to Phase 2 development in schizophrenia and to evaluate the potential for this mechanism in other populations, including dementia-related psychosis
Conference call and webcast scheduled for today at 8:30 a.m. EDT
Conference Call Information
Cerevel will host a conference call and webcast today, June 29, at 8:30 a.m. EDT to discuss the results of the Phase 1b trial of CVL-231 in schizophrenia. To access the call, please dial 833-665-0655 (domestic) or 702-495-1044 (international) and refer to conference ID 9584017. The live webcast and accompanying slides can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the company’s website for approximately 90 days.
https://finance.yahoo.com/news/cerevel-therapeutics-announces-positive-topline-103000730.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.